
Managing The First Few Weeks On Wegovy
The early gastrointestinal side effects are the most common reason people consider stopping. Most are manageable with simple changes.
Semaglutide, sold as Wegovy, launched in SA in August 2025 and recently saw substantial price reductions. Read the plain version of how it works, who it is for, and how to book an online consultation with a registered SA doctor.
The first GLP-1 medication approved in South Africa specifically for weight management, with added cardiovascular benefit data from the SELECT trial.
In late March 2026, Novo Nordisk announced significant price reductions on Wegovy in South Africa. The starting dose dropped from around R3,090 to roughly R1,873 per month. The maximum dose dropped 27 percent to around R3,746. A second reduction was submitted shortly after.
This makes Wegovy meaningfully more accessible in SA, particularly during the early titration months when most people are on the lower doses. See the full pricing breakdown.
The pages most people open before booking a consultation. Each is short, clear, and reviewed by a registered SA doctor.
Semaglutide, made by Novo Nordisk. What it actually is, how it relates to Ozempic, and why it matters.
Learn more →The GLP-1 mechanism in plain English. What happens to appetite, blood sugar, and digestion.
Learn more →Same active ingredient, different doses and indications. Why the distinction matters more than it sounds.
Compare →Two top choices in SA. Single pathway vs dual pathway, side effects, cost, and which suits whom.
Compare →The first weight medication approved to reduce cardiovascular events. The SELECT trial in plain terms.
Learn more →What to expect, what to watch for, and how most people manage the early gastrointestinal effects.
Read safety guide →The same Online Doctor SA process used by thousands of South Africans every month.
You answer a structured set of medical questions online. Height, weight, medical history, current medications, and any conditions a doctor needs to know about. About ten minutes.
An HPCSA registered doctor assesses whether Wegovy is appropriate and safe for you, picks the right starting dose, and flags anything that needs follow up.
The script is emailed to you. You collect from Clicks, Dis-Chem, your local pharmacy, or a delivery pharmacy. Confirm availability before paying for the consultation.
Yes. Wegovy launched in South Africa on 18 August 2025. It is SAHPRA registered for chronic weight management and is available at registered pharmacies across the country in five dose strengths.
Yes. Wegovy is a Schedule 4 prescription only medicine. A registered SA doctor must assess your medical history before a prescription can be issued. Buying semaglutide from unregulated online sources is risky. SAHPRA has issued warnings about falsified products.
Adults with a BMI of 30 or more, or BMI of 27 or more with at least one weight related condition such as type 2 diabetes, high blood pressure, sleep apnoea, or high cholesterol. Also approved for adolescents aged 12 and older with obesity. See full eligibility.
After Novo Nordisk's March 2026 price reductions, the lowest dose (0.25 mg) sits around R1,873 per month and the highest dose (2.4 mg) around R3,746. A second reduction was submitted shortly after. Pricing varies between pharmacies. See pricing details.
Appetite changes are often noticeable within the first two weeks on the starting 0.25 mg dose. Meaningful weight changes typically appear over the first few months, with most clinical trial response building through 68 weeks at full dose.

The early gastrointestinal side effects are the most common reason people consider stopping. Most are manageable with simple changes.

Roughly one in two South Africans on weight loss treatment is using an unregulated copy. Why this matters and what to look for.

The medication makes calorie reduction easier. That changes what kind of exercise actually matters during treatment.
An online consultation with a registered SA doctor takes around ten minutes. Your script lands in your inbox. No waiting room.
Start Consultation